Synlogic, Inc. Common Stock (SYBX)
Synlogic, Inc. is a clinical-stage biopharmaceutical company focused on developing synthetic biotic medicines—engineered live bacteria designed to treat various diseases. Utilizing proprietary synthetic biology platforms, the company aims to create innovative therapies for conditions such as metabolic disorders, inflammation, and other serious health issues.
Company News
CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the first quarter 2024 and provided a corporate update.
Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of -54.05% and 2.37%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
U.S. stocks traded mostly higher toward the end of trading, with the Nasdaq Composite gaining over 1% on Friday. The Dow traded down 0.09% to 38,691.21 while the NASDAQ rose 1.26% to 15,992.17. The S&P 500 also rose, gaining, 0.55% to 5,025.21. Check This Out: How To Earn $500 A Month From Principal Financial Group Stock Ahead Of Q4 Print L...
Price targets on these stocks are miles above their present market values.
The body's so-called germ squad in the gut can be tweaked, treating diseases including autism and Parkinson's disease.